Press Releases

BioCardia announces completion of two year follow-up for patients enrolled in the TABMMI trial. Enrollment of patients has begun in the extension of the trial intended to extend the safety data for the BioCardia intramyocardial delivery catheter system.

South San Francisco, CA., March 30, 2008

BioCardia announces completion of enrollment in the Transendocardial Autologous Bone Marrow in Myocardial Infarction (TABMMI) trial with perfect procedural safety results in all twenty patients treated. The trial led by principal investigator Dr. Luis de la Fuente presented two year follow-up on the first ten patients at the CRT meeting in Washington in February supporting long term safety and the therapeutic benefit of this approach. Additional larger placebo controlled safety and efficacy trials are planned for 2008.

Peter Altman, CEO of BioCardia states: "This important step brings us closer to realizing the potential of all cell based therapies for heart failure, and is to the credit of the dedication of the clinician investigators, the BioCardia staff, and the patients themselves. We feel the safety profile has been enhanced by the design features of the Helix and Morph catheter platforms which were developed for routine clinical use." For more information on this trial please see the National Institute of Health website www.clinicaltrials.gov.

About BioCardia
Headquartered in South San Francisco, BioCardia, Inc. is a leader in the development of catheter systems which enable local delivery of therapeutics to the heart and other organs. BioCardia currently is marketing the Morph® Catheter used through the vascular system for complex cases. Biotherapeutic clinical trials are ongoing using BioCardia's Helical Infusion System to deliver cell and gene therapies directly to the heart muscle. To date, BioCardia catheters have been used in more than 2000 clinical cases worldwide. More information available at www.biocardia.com.